GlassScriptPhysician profile
Renatta Jacobs
NPI 1235725326
$2,623.26
in general payments reported to CMS, 2019-2025
20 companies · $944 in 2025
The $944 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.91 · 2022: $483 · 2023: $509 · 2024: $647 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.80 |
| Education | $290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.55 | 2024-2025 | Calquence |
| Seagen INC. | $348.96 | 2022 | |
| Abbvie INC. | $326.12 | 2023-2025 | |
| Kite Pharma, INC. | $252.74 | 2024-2025 | Yescarta |
| Recordati_rare_diseases_inc. | $190.59 | 2024-2025 | Sylvant |
| Janssen Biotech, INC. | $174.05 | 2021-2025 | Imbruvica, Erleada |
| Astellas Pharma US INC | $161.67 | 2024-2025 | Cresemba, Xospata, Vyloy |
| Incyte Corporation | $144.96 | 2022-2025 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $96.00 | 2023 | Imbruvica |
| Amgen INC. | $81.83 | 2022-2023 | Blincyto |
| Alexion Pharmaceuticals, INC. | $59.19 | 2024-2025 | Ultomiris |
| Genmab U.S., INC. | $48.24 | 2024 | Epkinly |
| Daiichi Sankyo INC. | $38.72 | 2023-2025 | Vanflyta |
| Jazz Pharmaceuticals INC. | $28.55 | 2025 | |
| Emd Serono, INC. | $27.25 | 2023 | Bavencio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $25.90 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Legend Biotech USA INC. | $24.47 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $23.49 | 2023 | |
| Pfizer INC. | $15.91 | 2025 | |
| Morphosys, US INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renatta Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.